(Q41096699)

26 September 2017

The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts (English)

1 reference

26 September 2017

1 reference

1 reference

3

Andrea Mariani

1 reference

26 September 2017

6

Amy L Weaver

1 reference

26 September 2017

5

Michaela E Mc Gree

1 reference

26 September 2017

Mariam M Al Hilli

1

1 reference

26 September 2017

Jamie N Bakkum-Gamez

2

1 reference

26 September 2017

William A Cliby

4

1 reference

26 September 2017

Sean C Dowdy

7

1 reference

26 September 2017

Karl C Podratz

8

1 reference

26 September 2017

language of work or name

English

0 references

publication date

19 November 2015

1 reference

26 September 2017

1 reference

26 September 2017

140

1 reference

26 September 2017

2

1 reference

26 September 2017

270-276

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

26 September 2017

1 reference

Diabetes and risk of endometrial cancer: a population-based prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Diabetes mellitus and risk of endometrial cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Obesity, diabetes, and other factors in relation to survival after endometrial cancer diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

The association between metabolic abnormality and endometrial cancer: a large case-control study in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Metformin is associated with improved survival in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Metformin use and endometrial cancer survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Risk-adjusted outcomes in elderly endometrial cancer patients: implications of the contrasting impact of age on progression-free and cause-specific survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

The comparative assessment and improvement of quality of surgical care in the Department of Veterans Affairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Accuracy of frozen section diagnosis in surgical pathology: review of a 1-year experience with 24,880 cases at Mayo Clinic Rochester

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Authors' reply to editorial linked to their umbrella review of meta-analyses of observational studies on type 2 diabetes and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Diabetes and cancer: a consensus report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.11.019

10.1016/J.YGYNO.2015.11.019

7 January 2021

Identifiers

DOI

1 reference

26 September 2017

1 reference